Ortek Therapeutics

Redefining the standard for optimal oral health

startengine

Ortek develops two oral health products aimed at early cavity detection and enamel health. The Ortek-ECD is a FDA-cleared handheld device that measures the electrical conductance of enamel to detect early cavities on the biting surfaces of back teeth. It is a portable, point-of-care diagnostic tool with a base unit and disposable stainless steel tips, designed to complement X-rays by identifying lesions that may be missed in early stages. The ECD is used by dental professionals and has been adopted by hundreds of dentists in the United States.

BasicBites are sugar-free soft chews that leverage an oral microbiome approach to support enamel health. Available in chocolate and caramel, two chews per day are clinically shown to help maintain enamel health. The product contains arginine bicarbonate to support beneficial bacteria and a healthier oral pH environment, aiding calcium carbonate in enamel fortification. BasicBites have been on the market since 2014 and have accumulated over $1 million in cumulative sales with a limited marketing budget.

Ortek holds worldwide patent protection for the ECD and has two patent-pending variants for BasicBites. The company has a strategic alliance with The Research Foundation for The State University of New York and with researchers at Stony Brook University School of Dental Medicine, linking to exclusive licenses for two skin microbiome technologies intended for topical consumer and pharmaceutical products. BasicBites and related lines also pursue additional patent activity.

The market context indicates a large and growing global dental and oral care sector. The global dental services market has been valued in the hundreds of billions of dollars and is projected to grow toward the high end of that range by 2030; the dental equipment market is also sizable and expanding. An estimated portion of the global population experiences tooth decay, with particular prevalence in back teeth where X-rays may be less effective. In the United States, the dentist base is substantial (approximately 200,000 domestically; nearly 1 million globally), presenting a sizable addressable audience for ECD deployments and consumer products like BasicBites. The company intends to scale commercialization through expanded marketing, professional education, and broader adoption across dental offices and consumer channels.

Dr. Howard Glazer

Advisor

Shannon Nanne, RDH

Gordon Johnson

Mitchell Goldberg

President

Steven Sablotsky

Director

Fred Confessore

Michelle Strange, RDH

Anne Nugent Guignon, RDH, MPH, CSP

Dr. George Freedman

The update encourages readers to invest in Ortek Therapeutics, stating the Ortek-ECD® is FDA-cleared and patented in 20 countries, and that BasicBites® uses oral microbiome technology. It also mentions a newly announced agreement to develop Ortek's patented cutaneous microbiome body odor technology and claims Ortek is already selling two products to a growing customer base.

Just hours left to invest in Ortek Therapeutics

Ortek Therapeutics’ StartEngine equity crowdfunding campaign is ending in one day. The update says Ortek entered into an agreement with a microbial technology research and commercialization company to develop its patented cutaneous microbiome body odor technology, which could lead to an exclusive sublicense agreement.

Ortek campaign ends in 1 day; development agreement for patented skin microbiome technology

The update promotes Ortek Therapeutics’ Ortek-ECD® device for early detection of tooth decay and BasicBites® oral microbiome/enamel health product, with multiple dentist and dental hygienist testimonials about accuracy and usefulness. It also states there are two days left to invest.

Dental Professionals Endorse Ortek’s Ortek-ECD® and BasicBites®; 2 Days Left to Invest

Ortek Therapeutics announced it has entered into a development agreement to advance its cutaneous microbiome body odor patent with a company focused on advanced microbial technologies research and commercialization. If successful, the agreement could potentially lead to an exclusive sublicense; Ortek also noted it has exclusive licenses for two patents related to rebalancing skin microbiome to suppress body odor and combat drug-resistant bacteria, with no additional terms available.

Ortek Therapeutics Signs Development Agreement for Cutaneous Microbiome Body Odor Patent

The company thanks existing investors and invites new investors to invest in Ortek. It says there are 4 days left to invest.

4 days left to invest in Ortek Therapeutics

The update says the campaign is closing in 5 days and promotes Ortek Therapeutics’ FDA-cleared Class II medical device Ortek-ECD® and the BasicBites® product, including claims that BasicBites has over $1 million in cumulative sales. It also states that BasicBites Synergy Plus™ will be launched in Q4 and lists other product and market claims.

Closing in 5 Days: Ortek-ECD FDA-cleared device and BasicBites sales

The update says there are 6 days left to invest in Ortek on StartEngine and that Ortek has FDA-cleared technology. It also encourages readers to invest today and mentions an oral care market focus.

6 days left to invest in Ortek on StartEngine

Ortek says its initial ADA (American Dental Association) digital Morning Huddle newsletter ads for Ortek-ECD® were profitable and generated numerous dentist purchases across the country; the company plans a new series of digital ads starting in September and will consider print ads in ADA journals. The company also reports that an email blast to the Sjögren’s Foundation membership generated purchases of approximately 500 bags of BasicBites in one week and says it will start a new marketing campaign with print, digital, and social media strategies.

Ortek Expands Profitable ADA and Sjögren’s Foundation Marketing Campaigns

The update shares a testimonial from Brian Rosen, DDS, stating he used the Ortek-ECD® on hundreds of patients and finds it accurate, affordable, fast, and easy to use for early detection of tooth decay. It also notes that the campaign is closing in 11 days and highlights that the FDA-cleared Ortek-ECD uses electronic conductance technology to detect tiny cavities without radiation and indicates severity of decay.

Dentist testimonial on Ortek-ECD; campaign closing in 11 days

The update highlights Ortek-ECD® as an FDA-cleared Class II medical device, patented in 20 countries, and says it has been purchased by hundreds of dentists in the U.S. It also states BasicBites Soft Chews have over $1 million in cumulative sales and that Ortek is exclusively licensed two patents related to skin microbiome and body odor/drug-resistant bacteria; it adds that the crowdfunding campaign closes in 14 days.

14 Days Left: Top Reasons to Invest in Ortek Therapeutics

The community and insiders are investing in Ortek Therapeutics, Inc. Insiders have invested a total of $15,000 into the offering to date.

Insider investment update: insiders invested $15,000 to date

Ortek Therapeutics announced plans to introduce BasicBites Bedtime, a patent-pending oral care prebiotic soft chew combining magnesium, melatonin, and L-theanine. The update also notes that the campaign is “Closing in 19 Days.”

Ortek to Launch BasicBites Bedtime Oral Care Prebiotic Soft Chew

Ortek says its FDA-cleared Ortek-ECD® can immediately detect tiny cavities on back teeth by measuring electrical conductance of enamel, without using radiation. The update describes the device (portable base unit with digital display and audible alert, and disposable conductive stainless steel tips) and claims it performed highly effectively in a published peer-reviewed clinical study.

Ortek-ECD®: FDA-cleared device for detecting early tooth decay without radiation

The update states that the Ortek Therapeutics crowdfunding offering is closing soon and encourages investors to invest in Ortek. It also claims the company has already overcome commercialization hurdles and that its products are early in the oral care markets.

Ortek Therapeutics offering closing soon

Ortek announced it recently completed a successful routine U.S. Food and Drug Administration (FDA) inspection. The company states its Ortek-ECD® cavity detection system is an FDA-cleared Class II medical device and that routine inspections focus on quality system subsystems including CAPA, design controls, management controls, and production/process controls.

Ortek Therapeutics Completes Successful Routine FDA Inspection

Ortek Therapeutics has extended the offering campaign end date on StartEngine. Because the SEC requires reconfirmation when live offerings change, any investments that require reconfirmation will be contacted by StartEngine via email with further instructions.

Notice of material change: Ortek Therapeutics campaign end date extended

Ortek Therapeutics says it sold over 250 bags of BasicBites® in a single day, generating approximately $10,000 in net sales. The update also states cumulative BasicBites sales have surpassed $1 million to date, and that the company is raising funds to expand marketing for BasicBites and its FDA-cleared early cavity detection device, Ortek-ECD®.

Ortek reports selling 250+ BasicBites bags in one day, about $10k net sales

Ortek describes an example where its FDA-cleared ECD provided readings (site 1: 93; site 2: 04) when X-rays failed to detect a cavity on one tooth site. The company says the ECD helped enable early diagnosis and potentially avoid untreated decay.

Ortek’s FDA-cleared ECD detects hidden tooth decay (“It’s Magic”)

Ortek plans to extend its BasicBites® product line later this year with the patent-pending BasicBites Synergy Plus™ soft chew, combining its microbiome oral care technology with nutritional ingredients. The company expects to launch in Q4 and says it is expanding marketing efforts, including an ADA campaign and plans to sell on Amazon and its website.

Ortek to Launch BasicBites Synergy Plus Soft Chew Line Extension in Q4

The update cites a U.S. study reporting 2 million dental-related emergency room visits in 2018 and notes many patients with dental pain were prescribed antibiotics and some received opioids. It states that Ortek’s FDA-cleared ECD can detect early tooth decay without radiation and argues this could help reduce pain and downstream dental problems.

Why the Ortek-ECD Is Needed by Nearly Every Dental Office

Dentistry Today named Ortek-ECD® an Electronic Cavity Detection device a Top 100 Product for 2022, after earlier naming it a Top Innovative Product for 2022. The update says the ECD is FDA-cleared and patented in 20 countries, and is designed to detect tiny cavities without radiation.

Ortek-ECD named a Top 100 Product for 2022 by Dentistry Today

A published peer-reviewed clinical study reported that Ortek’s FDA-cleared, globally patented ECD early cavity detection system detected early biting surface cavities with 100% accuracy. The update also states the ECD has been adopted by hundreds of dental professionals.

Peer-reviewed study shows Ortek’s FDA-cleared ECD system is 100% accurate

Ortek Therapeutics announced it is working with the American Dental Association (ADA) to promote its FDA-cleared oral care products, Ortek-ECD® and BasicBites®. For the next several months, Ortek plans to advertise in the ADA’s Morning Huddle daily e-newsletter, augmenting its existing marketing in other dental publications.

Ortek begins ADA marketing campaign for FDA-cleared oral care products

Ortek’s FDA-cleared early cavity detection system (ECD) was featured in a presentation at the Gulf Shores Meeting of the Alabama Dental Association by Howard S. Glazer, DDS, FAGD, an Ortek advisor. The update also promotes the Ortek-ECD® as a radiation-free point-of-care diagnostic tool recommended to dental professionals.

Ortek ECD Presented at Alabama Dental Association Meeting

Ortek Therapeutics announced that its chocolate and caramel BasicBites® together have reached 500 “4.5 Star” reviews on Amazon. The update promotes BasicBites as a sugar-free soft chew with prebiotic technology and mentions its FDA-cleared ECD early cavity detection device.

BasicBites® reaches 500 “4.5-star” Amazon reviews

The update describes BasicBites® as a sugar-free soft chew intended to support enamel health via oral microbiome pH buffering, and notes each chew has 15 calories. It also states Ortek has an FDA-cleared and patented early cavity detection device (Ortek-ECD) and mentions a new promotional flyer for dental professionals.

BasicBites® product update citing oral microbiome research and Ortek’s FDA-cleared Ortek-ECD

Ortek Therapeutics shared a new print advertisement running in Dentistry Today promoting its FDA-cleared ECD device for painless tooth decay detection. The update also mentions the ECD’s retail price ($650) and claims it is used by hundreds of U.S. dentists, along with commercially available BasicBites sugar-free soft chews.

Ortek launches new ECD print advertisement in Dentistry Today

Ortek’s Early Bird 10% bonus share offer ends next Tuesday, May 31st at 11:00 am (Eastern Time). The update thanks early investors and encourages investing in Ortek.

Ortek’s 10% Early Bird Bonus Shares End Next Tuesday (May 31, 11:00am ET)

Ortek’s Super Early Bird 15% bonus shares end tomorrow at 11:00 AM Eastern Time. The company says it has raised over $47,000 in less than two weeks.

Ortek 15% Bonus Shares End Tomorrow at 11:00 AM ET

Ortek Therapeutics says it raised $45K in just over a week from its first 35 investors and thanks them for their support. The update also states the Super Early Bird 15% bonus shares are still available for a limited time.

$45K Raised in Just Over a Week; Super Early Bird 15% Bonus Still Available

Ortek announced that the Brazilian Patent and Trademark Office issued a patent for the Ortek-ECD® electronic cavity detection device. With this new Brazilian patent, the device is covered by 20 issued patents in major global markets; the company also states the ECD is FDA-cleared and in use by hundreds of dentists in the U.S.

Brazil issues patent for Ortek-ECD®, bringing total issued patents to 20

A feature article about Ortek Therapeutics’ FDA-cleared and internationally patented early cavity detection device has been published in Dentistry Today. The article describes the benefits of the technology for patients, dental professionals, and their practices.

Dentistry Today publishes feature on Ortek-ECD early cavity detection device

The company reports that insiders invested $7,500 into the offering for Ortek Therapeutics, Inc. The update includes an invitation to invest and references the offering materials and risk factors.

Insider investment: $7,500 invested into the Ortek Therapeutics offering

Ortek Therapeutics is raising capital on StartEngine to support marketing for two oral care products: the FDA-cleared Ortek-ECD device and BasicBites sugar-free soft chews. The company says early investors will receive bonuses, and it plans to use the raised funds for multi-media marketing programs.